Search research articles
Contact Us
Filters
Showing results (1-10 of 14) with videos related to
Page
of 2
Sort By:
The Journal of Community and Supportive Oncology
|
June 28, 2014
Delayed response in ipilimumab therapy
Ahmed Megahed, Peter Faulhaber, Tycel Phillips, et al.
Cancer Research
|
June 17, 2005
Novel cellular genes essential for transformation of endothelial cells by Kaposi's sarcoma-associated herpesvirus
Camilo Raggo, Rebecca Ruhl, Shane McAllister, et al.
Cancer Biology & Therapy
|
May 21, 2014
Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers
Kriti Mittal, Henry Koon, Paul Elson, et al.
International Journal of Clinical Oncology
|
July 20, 2019
Immune checkpoint inhibitor-induced sarcoidosis-like granulomas
Pooja H Rambhia, Barbara Reichert, Jeffrey F Scott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 28, 2003
Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma
Jared A Gollob, Korina G Veenstra, Robert A Parker, et al.
Journal of Cancer Research and Clinical Oncology
|
April 15, 2016
Parotid melanoma of unknown primary
Jeffrey F Scott, Cheryl L Thompson, Ritva Vyas, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
February 25, 2009
Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma
Daniel C Cho, Igor Puzanov, Meredith M Regan, et al.
Cancer Research
|
May 11, 2011
MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents
Weiwen Fan, Zhe Tang, Lihong Yin, et al.
Journal of Translational Medicine
|
November 4, 2010
Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial
Helen Gogas, Urania Dafni, Henry Koon, et al.
Investigational New Drugs
|
June 20, 2020
Phase I clinical trial of temozolomide and methoxyamine (TRC-102), an inhibitor of base excision repair, in patients with advanced solid tumors
Jennifer R Eads, Smitha S Krishnamurthi, Joel Saltzman, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 14) with videos related to
Sort By:
Page
of 2
The Journal of Community and Supportive Oncology
|
June 28, 2014
Delayed response in ipilimumab therapy
Ahmed Megahed, Peter Faulhaber, Tycel Phillips, et al.
Cancer Research
|
June 17, 2005
Novel cellular genes essential for transformation of endothelial cells by Kaposi's sarcoma-associated herpesvirus
Camilo Raggo, Rebecca Ruhl, Shane McAllister, et al.
Cancer Biology & Therapy
|
May 21, 2014
Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers
Kriti Mittal, Henry Koon, Paul Elson, et al.
International Journal of Clinical Oncology
|
July 20, 2019
Immune checkpoint inhibitor-induced sarcoidosis-like granulomas
Pooja H Rambhia, Barbara Reichert, Jeffrey F Scott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 28, 2003
Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma
Jared A Gollob, Korina G Veenstra, Robert A Parker, et al.
Journal of Cancer Research and Clinical Oncology
|
April 15, 2016
Parotid melanoma of unknown primary
Jeffrey F Scott, Cheryl L Thompson, Ritva Vyas, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
February 25, 2009
Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma
Daniel C Cho, Igor Puzanov, Meredith M Regan, et al.
Cancer Research
|
May 11, 2011
MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents
Weiwen Fan, Zhe Tang, Lihong Yin, et al.
Journal of Translational Medicine
|
November 4, 2010
Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial
Helen Gogas, Urania Dafni, Henry Koon, et al.
Investigational New Drugs
|
June 20, 2020
Phase I clinical trial of temozolomide and methoxyamine (TRC-102), an inhibitor of base excision repair, in patients with advanced solid tumors
Jennifer R Eads, Smitha S Krishnamurthi, Joel Saltzman, et al.
Page
of 2